Cargando…

Prevalence of oral anticoagulant use among people with and without Alzheimer’s disease

BACKGROUND: Although cardio- and cerebrovascular diseases are common among people with Alzheimer’s disease (AD), it is unknown how the prevalence of oral anticoagulant (OAC) use changes in relation to AD diagnosis. We investigated the prevalence of OAC use in relation to AD diagnosis in comparison t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali Babar, Barkat, Vu, Mai, Koponen, Marjaana, Taipale, Heidi, Tanskanen, Antti, Kettunen, Raimo, Tiihonen, Miia, Hartikainen, Sirpa, Tolppanen, Anna-Maija
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148467/ https://www.ncbi.nlm.nih.gov/pubmed/35643439 http://dx.doi.org/10.1186/s12877-022-03144-x

Ejemplares similares

Coronary Revascularization and Postoperative Outcomes in People With and Without Alzheimer’s Disease
por: Vu, Mai, et al.
Publicado: (2021)

Automated multi-dose dispensing in persons with and without Alzheimer’s disease—impacts on pharmacotherapy
por: Vallius, Sanna, et al.
Publicado: (2021)

Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2018)

Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
por: Taipale, Heidi, et al.
Publicado: (2014)

Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland
por: Lavikainen, Piia, et al.
Publicado: (2020)

Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2013)

Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study
por: Taipale, Heidi, et al.
Publicado: (2019)

Statin discontinuation in persons with and without Alzheimer’s disease
por: Vu, Mai, et al.
Publicado: (2022)

Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
por: Taipale, Heidi, et al.
Publicado: (2016)

Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer’s disease in 2005-2011
por: Tolppanen, Anna-Maija, et al.
Publicado: (2017)

Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2017)

Causes of death in a nationwide cohort of community-dwellers with Alzheimer’s disease
por: Tolppanen, Anna-Maija, et al.
Publicado: (2020)

Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
por: Lintula, Eveliina, et al.
Publicado: (2019)

From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
por: Tanskanen, Antti, et al.
Publicado: (2015)

From prescriptions to drug use periods - things to notice
por: Tanskanen, Antti, et al.
Publicado: (2014)

Drug exposure in register-based research—An expert-opinion based evaluation of methods
por: Tanskanen, Antti, et al.
Publicado: (2017)

Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
por: Pisa, Federica, et al.
Publicado: (2021)

Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
por: Tiihonen, Miia, et al.
Publicado: (2016)

Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer’s Disease
por: Sarycheva, Tatyana, et al.
Publicado: (2018)

Changes in the use of diabetes drugs among community-dwelling people with Alzheimer’s disease
por: López-Rubio, Carlos, et al.
Publicado: (2021)

Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
por: Sarycheva, Tatyana, et al.
Publicado: (2018)

Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease
por: Sarycheva, Tatyana, et al.
Publicado: (2020)

Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes
por: Sunnarborg, Katriina, et al.
Publicado: (2022)

Incidence of antidepressant use among community dwellers with and without Parkinson’s disease – a nationwide cohort study
por: Hentilä, Eerik, et al.
Publicado: (2021)

Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis
por: Paakinaho, Anne, et al.
Publicado: (2022)

Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer’s Disease: A National Population Cohort Study
por: Gnjidic, Danijela, et al.
Publicado: (2014)

β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
por: Paakinaho, Anne, et al.
Publicado: (2023)

Length of hospital stay after hip fracture and readmission rates of persons with and without Alzheimer’s disease: a matched cohort study
por: Rajamaki, Blair, et al.
Publicado: (2020)

Recent hospitalization and risk of antidepressant initiation in people with Parkinson’s disease
por: Hämäläinen, Iida, et al.
Publicado: (2022)

Use of α1‐adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease
por: Latvala, Laura, et al.
Publicado: (2022)

Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
por: Puranen, Arto, et al.
Publicado: (2023)

Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer’s disease—nested case-control study
por: Taipale, H., et al.
Publicado: (2019)

Identification of Drugs Associated with Lower Risk of Parkinson’s Disease Using a Systematic Screening Approach in a Nationwide Nested Case–Control Study
por: Koponen, Marjaana, et al.
Publicado: (2022)

Risk factors of pneumonia in persons with and without Alzheimer’s disease: a matched cohort study
por: Järvinen, Heli, et al.
Publicado: (2023)

The effect of comorbidities on survival in persons with Alzheimer’s disease: a matched cohort study
por: Rajamaki, Blair, et al.
Publicado: (2021)

History of Medically Treated Diabetes and Risk of Alzheimer Disease in a Nationwide Case-Control Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2013)

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
por: Taipale, Heidi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m2uri7ohikfv0ue9retj81bouj